This blog series highlights pertinent publications that were featured in MCI’s monthly newsletter editions in the third quarter of 2025. The purpose of this blog is to report interesting or relevant work from MCI Fellows, Grantees, staff members, and other community authors in the field of male contraception.
This editorial highlights and contextualizes the progress made by YourChoice Pharmaceuticals and YCT-529 in the recent publication of their Phase 1A safety data.
From concept to the clinic: Retinoic acid receptor α antagonist YCT‐529, an oral non‐hormonal male contraceptive – Taher – Andrology – Wiley Online Library
This manuscript, from the lab of MCI grantee, Dr. Gunda Georg, and current MCI fellow outlines the progress of Retinoic acid receptor α antagonist YCT-529. YCT-529 has completed a first-in-class, double-blind, placebo-controlled Phase I clinical safety study in 16 men and is currently being investigated in a Phase Ib/IIa clinical study.
This preprint from MCI staff in collaboration with FHI360, the Gates Foundation, and Nuapoch outlines an update of the CTI Tracker, a resource which houses information on potential contraceptive leads in early development, products in pre-clinical and clinical development, and products with single-country regulatory approval.